Wendy W. Pang

Hematology | Oncology
300 Pasteur Dr
Stanford, CA 94305

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.

Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.

Journal: Blood
Published: November 10, 2025

Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.

Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.

Journal: Blood
Published: November 10, 2025

Mast cell depletion and repopulation dynamics define briquilimab efficacy in a mouse model of allergic asthma.

Mast cell depletion and repopulation dynamics define briquilimab efficacy in a mouse model of allergic asthma.

Journal: The Journal of allergy and clinical immunology
Published: October 03, 2025

Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT.

Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT.

Journal: Allergy
Published: June 25, 2025

Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates.

Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates.

Journal: The Journal of allergy and clinical immunology
Published: February 12, 2025

Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.

Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.

Journal: Nature medicine
Published: June 06, 2024

Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.

Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.

Journal: Transplantation and cellular therapy
Published: April 24, 2024

Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells.

Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells.

Journal: Annual review of medicine
Published: January 27, 2022

5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

Journal: Blood advances
Published: November 18, 2020

Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.

Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.

Journal: Blood advances
Published: April 10, 2019

RUNX3 levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance.

RUNX3 levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance.

Journal: Haematologica
Published: October 19, 2018

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.

Journal: Nature communications
Published: July 13, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026